title: Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
abstract: BACKGROUND
  Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through red blood cell transfusions.Repeated transfusions result in an excessive accumulation of iron in the body (iron overload), removal of which is achieved through iron chelation therapy. Desferrioxamine mesylate (desferrioxamine) is one of the most widely used iron chelators. Substantial data have shown the beneficial effects of desferrioxamine, although adherence to desferrioxamine therapy is a challenge. Alternative oral iron chelators, deferiprone and deferasirox, are now commonly used. Important questions exist about whether desferrioxamine, as monotherapy or in combination with an oral iron chelator, is the best treatment for iron chelation therapy.
  
  
  OBJECTIVE
  To determine the effectiveness (dose and method of administration) of desferrioxamine in people with transfusion-dependent thalassaemia.To summarise data from trials on the clinical efficacy and safety of desferrioxamine for thalassaemia and to compare these with deferiprone and deferasirox.
  
  
  METHODS
  We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. We also searched MEDLINE, EMBASE, CENTRAL (The Cochrane Library), LILACS and other international medical databases, plus ongoing trials registers and the Transfusion Evidence Library (www.transfusionevidencelibrary.com). All searches were updated to 5 March 2013.
  
  
  METHODS
  Randomised controlled trials comparing desferrioxamine with placebo, with another iron chelator, or comparing two schedules or doses of desferrioxamine, in people with transfusion-dependent thalassaemia.
  
  
  METHODS
  Six authors working independently were involved in trial quality assessment and data extraction. For one trial, investigators supplied additional data upon request.
  
  
  RESULTS
  A total of 22 trials involving 2187 participants (range 11 to 586 people) were included. These trials included eight comparisons between desferrioxamine alone and deferiprone alone; five comparisons between desferrioxamine combined with deferiprone and deferiprone alone; eight comparisons between desferrioxamine alone and desferrioxamine combined with deferiprone; two comparisons of desferrioxamine with deferasirox; and two comparisons of different routes of desferrioxamine administration (bolus versus continuous infusion). Overall, few trials measured the same or long-term outcomes. Seven trials reported cardiac function or liver fibrosis as measures of end organ damage; none of these included a comparison with deferasirox.Five trials reported a total of seven deaths; three in patients who received desferrioxamine alone, two in patients who received desferrioxamine and deferiprone. A further death occurred in a patient who received deferiprone in another who received deferasirox alone. One trial reported five further deaths in patients who withdrew from randomised treatment (deferiprone with or without desferrioxamine) and switched to desferrioxamine alone.One trial planned five years of follow up but was stopped early due to the beneficial effects of a reduction in serum ferritin levels in those receiving combined desferrioxamine and deferiprone treatment compared with deferiprone alone. The results of this and three other trials suggest an advantage of combined therapy with desferrioxamine and deferiprone over monotherapy to reduce iron stores as measured by serum ferritin. There is, however, no evidence for the improved efficacy of combined desferrioxamine and deferiprone therapy against monotherapy from direct or indirect measures of liver iron.Earlier trials measuring the cardiac iron load indirectly by measurement of the magnetic resonance imaging T2* signal had suggested deferiprone may reduce cardiac iron more quickly than desferrioxamine. However, meta-analysis of two trials showed a significantly lower left ventricular ejection fraction in patients who received desferrioxamine alone compared with those who received combination therapy using desferrioxamine with deferiprone.Adverse events were recorded by 18 trials. These occurred with all treatments, but were significantly less likely with desferrioxamine than deferiprone in one trial, relative risk 0.45 (95% confidence interval 0.24 to 0.84) and significantly less likely with desferrioxamine alone than desferrioxamine combined with deferiprone in two other trials, relative risk 0.33 (95% confidence interval 0.13 to 0.84). In particular, four studies reported permanent treatment withdrawal due to adverse events from deferiprone; only one of these reported permanent withdrawals associated with desferrioxamine. Adverse events also occurred at a higher frequency in patients who received deferasirox than desferrioxamine in one trial. Eight trials reported local adverse reactions at the site of desferrioxamine infusion including pain and swelling. Adverse events associated with deferiprone included joint pain, gastrointestinal disturbance, increases in liver enzymes and neutropenia; adverse events associated with deferasirox comprised increases in liver enzymes and renal impairment. Regular monitoring of white cell counts has been recommended for deferiprone and monitoring of liver and renal function for deferasirox.In summary, desferrioxamine and the oral iron chelators deferiprone and deferasirox produce significant reductions in iron stores in transfusion-dependent, iron-overloaded people. There is no evidence from randomised clinical trials to suggest that any one of these has a greater reduction of clinically significant end organ damage, although in two trials, combination therapy with desferrioxamine and deferiprone showed a greater improvement in left ventricular ejection fraction than desferrioxamine used alone.
  
  
  CONCLUSIONS
  Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate. Oral deferasirox has been licensed for use in children aged over six years who receive frequent blood transfusions and in children aged two to five years who receive infrequent blood transfusions. In the absence of randomised controlled trials with long-term follow up, there is no compelling evidence to change this conclusion.Worsening iron deposition in the myocardium in patients receiving desferrioxamine alone would suggest a change of therapy by intensification of desferrioxamine treatment or the use of desferrioxamine and deferiprone combination therapy.Adverse events are increased in patients treated with deferiprone compared with desferrioxamine and in patients treated with combined deferiprone and desferrioxamine compared with desferrioxamine alone. People treated with all chelators must be kept under close medical supervision and treatment with deferiprone or deferasirox requires regular monitoring of neutrophil counts or renal function respectively. There is an urgent need for adequately-powered, high-quality trials comparing the overall clinical efficacy and long-term outcomes of deferiprone, deferasirox and desferrioxamine.
authors: Systematic Review Initiative, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, Oxon, UK, OX3 9BQ.
authors: Sheila A
authors: SA
authors: Fisher
authors: Susan J
authors: SJ
authors: Brunskill
authors: Carolyn
authors: C
authors: Doree
authors: Sarah
authors: S
authors: Gooding
authors: Onima
authors: O
authors: Chowdhury
authors: David J
authors: DJ
authors: Roberts
mesh_terms: D001565:Benzoates / Q000008:administration & dosage; D015913:Chelation Therapy; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology; D011728:Pyridones / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D017262:Siderophores / Q000008:administration & dosage*; D013789:Thalassemia / Q000628:therapy*; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D017262:Siderophores; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox
references: Acta Haematol. 1990;84(3):113-7
references: 2123060
references: Clin Ther. 2007 May;29(5):909-917
references: 17697909
references: Haematologica. 2004 Apr;89(4):ELT07
references: 15075120
references: Br J Haematol. 1997 Sep;98(3):597-600
references: 9332313
references: Br J Haematol. 1992 Oct;82(2):431-6
references: 1419825
references: Lancet. 1983 Jul 23;2(8343):181-4
references: 6135026
references: Nat Rev Genet. 2001 Apr;2(4):245-55
references: 11283697
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: N Engl J Med. 1990 Sep 13;323(11):713-9
references: 2388669
references: Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:96-9
references: 7886617
references: Lancet. 1989 Jul 1;2(8653):27-30
references: 2567801
references: Br J Haematol. 2003 Apr;121(1):187-9
references: 12670352
references: Br J Haematol. 1990 Oct;76(2):295-300
references: 2094333
references: J Pediatr. 1978 Apr;92(4):648-52
references: 633032
references: Lancet. 1981 Jan 3;1(8210):51
references: 6109092
references: Hematology. 2012 May;17(3):183-6
references: 22664119
references: Blood. 2002 Sep 1;100(5):1566-9
references: 12176871
references: Ann N Y Acad Sci. 1998 Jun 30;850:469-70
references: 9668587
references: Eur J Pediatr. 1996 May;155(5):368-72
references: 8741032
references: Bone Marrow Transplant. 1993;12 Suppl 1:5-8
references: 8374563
references: Ann N Y Acad Sci. 1990;612:369-77
references: 2291564
references: J Pediatr. 1988 Oct;113(4):661-9
references: 3171791
references: N Engl J Med. 1977 Aug 25;297(8):418-23
references: 882111
references: Kidney Int. 1994 Aug;46(2):467-70
references: 7967359
references: Lancet. 2002 Aug 17;360(9332):516-20
references: 12241655
references: Arch Iran Med. 2009 Sep;12(5):488-91
references: 19722772
references: Transfus Sci. 2000 Dec;23(3):239-40
references: 11099900
references: Hematology. 2007 Dec;12(6):577-85
references: 17852442
references: Aust N Z J Med. 1993 Dec;23(6):656-61
references: 8141693
references: Hemoglobin. 2011;35(3):206-16
references: 21599433
references: Am J Hematol. 1992 Sep;41(1):61-3
references: 1503101
references: N Engl J Med. 1995 Apr 6;332(14):918-22
references: 7877649
references: Indian Pediatr. 2004 Jan;41(1):21-7
references: 14767084
references: Vox Sang. 2010 Jul;99 Suppl 1:1-516
references: 20591082
references: Circulation. 2007 Apr 10;115(14):1876-84
references: 17372174
references: N Engl J Med. 1998 Aug 13;339(7):417-23
references: 9700174
references: J Pediatr Hematol Oncol. 2006 Jan;28(1):11-6
references: 16394886
references: J Cardiovasc Magn Reson. 2011 Jul 06;13:34
references: 21733147
references: Haematologica. 2003 Dec;88(12):1423-5
references: 14687998
references: Br J Haematol. 1998 Nov;103(2):361-4
references: 9827905
references: Clin Endocrinol (Oxf). 1994 Jun;40(6):791-8
references: 8033371
references: Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196-208
references: 12064916
references: Blood. 2006 May 1;107(9):3455-62
references: 16352812
references: Clin Sci Mol Med. 1978 Jan;54(1):99-106
references: 620500
references: Hemoglobin. 2006;30(2):263-74
references: 16798652
references: Blood. 2000 May 1;95(9):2776-9
references: 10779420
references: Lancet. 1978 Jun 3;1(8075):1178-81
references: 77945
references: Br J Haematol. 2009 Apr;145(2):245-54
references: 19236376
references: J Pediatr. 1997 Jan;130(1):86-8
references: 9003855
references: Ann Hematol. 2012 Sep;91(9):1443-9
references: 22572843
references: Haematologica. 1995 Jul-Aug;80(4):300-4
references: 7590497
references: Eur Radiol. 2003 Jan;13(1):12-6
references: 12541105
references: Haematologica. 2000 Feb;85(2):115-7
references: 10681716
references: Blood. 1988 Apr;71(4):1124-9
references: 3355891
references: J Pediatr. 1991 Apr;118(4 Pt 1):540-5
references: 2007928
references: Blood. 2003 Sep 1;102(5):1583-7
references: 12763939
references: J Cardiovasc Magn Reson. 2008 Feb 25;10:12
references: 18298856
references: Blood. 2006 May 1;107(9):3738-44
references: 16352815
references: Br J Haematol. 1992 Oct;82(2):460-6
references: 1419829
references: Best Pract Res Clin Haematol. 2002 Jun;15(2):329-68
references: 12401311
references: Lancet. 1992 Mar 21;339(8795):699-701
references: 1347583
references: Blood. 1998 Jan 1;91(1):295-300
references: 9414297
references: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004450
references: 16235363
references: ISRN Hematol. 2012;2012:139862
references: 23316378
references: Br J Haematol. 1998 Jun;101(3):413-5
references: 9633879
references: Transfusion. 2013 Aug;53(8):1722-9
references: 23241074
references: Eur J Haematol. 2010 Jul;85(1):36-42
references: 20331740
references: J Clin Invest. 1983 Mar;71(3):429-39
references: 6826715
references: N Engl J Med. 1994 Sep 1;331(9):574-8
references: 8047081
references: Hematology. 1999;4(1):67-76
references: 11399554
references: Lancet. 1979 Oct 20;2(8147):819-21
references: 90918
references: Hemoglobin. 2010;34(1):95-106
references: 20113293
references: Am J Dis Child. 1990 May;144(5):565-9
references: 2330923
references: Lancet. 1990 Nov 24;336(8726):1275-9
references: 1978115
references: Lancet. 1976 Dec 11;2(7998):1278-80
references: 63749
references: Acta Haematol. 2000;104(2-3):99-102
references: 11154982
references: N Engl J Med. 1994 Sep 1;331(9):567-73
references: 8047080
references: Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51
references: 19233692
references: Br J Haematol. 1969 Dec;17(6):563-8
references: 5357744
references: N Engl J Med. 1985 Jun 20;312(25):1600-3
references: 4000198
references: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476
references: 22336831
references: Haematologica. 2006 Sep;91(9):1241-3
references: 16956824
references: Haematologica. 2012 Jun;97(6):842-8
references: 22271905
references: Ann Hematol. 2008 Jul;87(7):545-50
references: 18351337
references: Lancet. 2000 Jun 10;355(9220):2051-2
references: 10885361
references: Acta Haematol. 1996;95(1):26-36
references: 8604584
references: Br J Haematol. 2002 Jul;118(1):330-6
references: 12100170
references: Br Med J. 1974 Apr 6;2(5909):16-20
references: 4821036
references: Blood. 2008 Jan 15;111(2):583-7
references: 17951527
references: Haematologica. 1990 Sep-Oct;75 Suppl 5:84-8
references: 2086385
references: Haematologica. 2006 Jul;91(7):873-80
references: 16818273
references: Am J Dis Child. 1989 Sep;143(9):1077-80
references: 2486554
references: Int J Epidemiol. 2002 Feb;31(1):140-9
references: 11914310
references: N Engl J Med. 1999 Jul 8;341(2):99-109
references: 10395635
references: Lancet. 1981 May 9;1(8228):1059
references: 6112440
references: J Med Ethics. 2004 Feb;30(1):1-7
references: 14872065
references: Ann N Y Acad Sci. 1998 Jun 30;850:227-31
references: 9668544
references: Blood. 2006 May 1;107(9):3436-41
references: 16627763
references: Blood. 2000 Feb 15;95(4):1229-36
references: 10666195
references: Bone Marrow Transplant. 2000 Mar;25(6):653-6
references: 10734300
references: Eur J Haematol. 2007 Jan;78(1):48-51
references: 17042774
references: Eur J Haematol. 2001 Jul;67(1):30-4
references: 11553264
references: Ann N Y Acad Sci. 2005;1054:183-5
references: 16339664
references: Am J Hematol. 2012 Jul;87(7):732-3
references: 22622672
references: Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12
references: 3122880
references: N Engl J Med. 2002 Oct 24;347(17):1368-71
references: 12397199
references: Eur J Haematol. 2006 Mar;76(3):183-92
references: 16451393
references: Haematologica. 2012 Jun;97(6):835-41
references: 22180427
references: Haematologica. 2008 Jun;93(6):817-25
references: 18469351
references: Int J Hematol. 1991 Oct;54(5):371-5
references: 1756248
references: Haematologica. 1998 Sep;83(9):788-90
references: 9825575
references: Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9
references: 20678715
references: Acta Paediatr. 1999 May;88(5):550-2
references: 10426179
references: Lancet. 1983 Oct 8;2(8354):859-60
references: 6137689
references: Blood Cells Mol Dis. 2004 Jan-Feb;32(1):139-40; author reply 141-2
references: 14757428
references: Acta Haematol. 1999;102(1):17-21
references: 10473883
references: Hematology Am Soc Hematol Educ Program. 2001;:47-61
references: 11722978
references: Baillieres Clin Haematol. 1989 Apr;2(2):459-74
references: 2660937
references: Blood. 1997 Feb 1;89(3):739-61
references: 9028304
references: Semin Hematol. 1990 Apr;27(2):101-4
references: 2190316
references: Eur J Haematol. 1999 Oct;63(4):267-8
references: 10530416
references: Br J Haematol. 1998 Jun;101(3):399-406
references: 9633877
references: Br J Haematol. 2000 Oct;111(1):2-5
references: 11091177
references: Ann N Y Acad Sci. 1974;232(0):221-5
references: 4528431
references: Haematologica. 2007 Dec;92(12):1599-606
references: 18055982
references: Birth Defects Orig Artic Ser. 1976;12(8):177-85
references: 795481
references: Br J Haematol. 2007 Aug;138(4):407-21
references: 17659052
references: Br J Haematol. 1990 Dec;76(4):550-3
references: 2265118
references: Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1081-4
references: 6802413
references: Infect Immun. 1985 Mar;47(3):774-9
references: 3972453
references: Hemoglobin. 2003 May;27(2):63-76
references: 12779268
references: Br J Haematol. 2000 Feb;108(2):305-12
references: 10691860
references: Fundam Clin Pharmacol. 2009 Jun;23(3):359-65
references: 19453758
references: Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004839
references: 23966105
references: Hemoglobin. 2006;30(2):257-62
references: 16798651
references: Haematologica. 1998 Jun;83(6):496-501
references: 9676021
references: J Pediatr Hematol Oncol. 2007 Sep;29(9):598-601
references: 17805032
references: N Engl J Med. 1976 Jun 24;294(26):1421-3
references: 1272274
references: Br J Haematol. 2003 Jun;121(6):938-48
references: 12786807
references: Ceylon Med J. 2002 Dec;47(4):119-21
references: 12661341
references: Prog Clin Biol Res. 1989;309:27-33
references: 2675094
references: J Cardiovasc Magn Reson. 2013 Jan 16;15:1
references: 23324167
references: Acta Endocrinol (Copenh). 1991 Jan;124(1):23-30
references: 1900379
references: Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121
references: 19068191
references: J Cardiovasc Magn Reson. 2012 Jan 25;14:8
references: 22277065
references: Hemoglobin. 2009;33(5):312-22
references: 19814677
references: Blood. 2003 Jun 15;101(12):5089-90; author reply 5090-1
references: 12788794
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120